Deferasirox AUC efficacy cutoff and role of pharmacogenetics

European Journal of Clinical Pharmacology

Volumn 72, Issue 9, 2016, Pages 1155-1157

  Allegra, S ^a   Cusato, J ^a   De Francia, S ^b   Massano, D ^b   Piga, A ^b   D'Avolio A ^a  

^a AMEDEO DI SAVOIA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; GENOMIC DNA; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

AREA UNDER THE CURVE; BETA THALASSEMIA; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; LETTER; PHARMACOGENETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; BETA-THALASSEMIA; BLOOD; FEMALE; GENETICS; GENOTYPE; MALE; METABOLISM; TREATMENT OUTCOME;

AREA UNDER CURVE; BENZOATES; BETA-THALASSEMIA; FEMALE; GENOTYPE; HUMANS; IRON CHELATING AGENTS; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; TRIAZOLES;

EID: 84969900510     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-016-2070-9     Document Type: Letter

References (5)

1. Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK, Grant FD, Paley C, Shannon M, Neufeld EJ (2009) Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 114(19):4009–4013. doi:10.1182/blood-2009-05-222729
2. Bruin GJ, Faller T, Wiegand H, Schweitzer A, Nick H, Schneider J, Boernsen KO, Waldmeier F (2008) Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos 36(12):2523–2538. doi:10.1124/dmd.108.022962
3. Cusato J, Allegra S, Massano D, De Francia S, Piga A, D’Avolio A (2015) Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J 15(3):263–271. doi:10.1038/tpj.2014.65
4. De Francia S, Massano D, Piccione FM, Pirro E, Racca S, Di Carlo F, Piga A (2012) A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. J Chromatogr B Analyt Technol Biomed Life Sci 893-894: 127-133 DOI 10.1016/j.jchromb.2012.02.047
5. Delord M, Rousselot P, Cayuela JM, Sigaux F, Guilhot J, Preudhomme C, Guilhot F, Loiseau P, Raffoux E, Geromin D, Genin E, Calvo F, Bruzzoni-Giovanelli H (2013) High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget 4(10):1582–1591. doi:10.18632/oncotarget.1050